Introduction of allergenic foods after treatment with omalizumab
Journal of Allergy and Clinical Immunology · 2025-08 · 156 (2) · 394-405
DOI: 10.1016/j.jaci.2025.05.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025-08. Verfasst von Jennifer Dantzer und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Md. Electronic address: jwrubel1@jh.edu. Hauptthemen laut MEDLINE: Omalizumab, Food Hypersensitivity, Allergens, Anti-Allergic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, Emory University.
Abstract (Originalsprache)
BACKGROUND: Omalizumab has been shown to increase reaction thresholds to allergenic foods during treatment. Little is known about its potential to permit introduction of allergenic foods. OBJECTIVE: The aim of this study was to examine introduction of allergenic foods after stopping treatment with omalizumab. METHODS: The first 60 participants completing OUtMATCH (Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants) stage 1 entered a 24-week open label extension, followed by entry into protocol stage 3, which could include dietary consumption (DC) of retail allergenic foods, rescue oral immunotherapy, or allergen avoidance, depending on the results of the final food challenges and participant preferences. RESULTS: A total of 60 participants were included (58% male, median age 8.5 years, age range 1-20 years). The study foods included peanut (n = 60), cashew (n = 28), egg (n = 27), milk (n = 25), walnut (n = 23), wheat (n = 9), and hazelnut (n = 8). Of the initial treatment plans, 82% included DC. DC success was defined as a median daily consumption of at least 300 mg of food protein over 12 months, with the data analyzed in quarterly intervals. Overall, greater success was observed for milk, egg, or wheat (61%-70%) than for peanut or tree nuts (38%-56%). Allergenic food consumption generally declined over time, except in the cases of wheat, with greater variability in median consumption for egg and milk relative to nuts. Reduced consumption appeared to be related to both symptoms and patient preference. The only predictor of DC success was a higher screening challenge threshold. Adverse events included episodes of anaphylaxis, epinephrine use, and 2 diagnoses of eosinophilic esophagitis related to DC. CONCLUSIONS: In this first study of introduction of retail food following omalizumab treatment, most participants were able to introduce allergenic foods in a dietary form, although adverse reactions did occur and many participants returned to avoidance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Md. Electronic address: jwrubel1@jh.edu.
- Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC.
- Elliot and Roslyn Jaffe Food Allergy Institute, Division of Allergy and Immunology, Kravis Children's Hospital, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY.
- Division of Pediatric Allergy and Immunology and Food Allergy Center, Massachusetts General Hospital, Boston, Mass.
- Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Md.
- Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, Calif.
Förderung
- NIAID NIH HHS
- NCATS NIH HHS
- Emory University
- Harvard Medical School
- University of Pennsylvania
- Stanford University
- Johns Hopkins University
- Icahn School of Medicine at Mount Sinai
Zitieren
APA
Dantzer, J., Virkud, Y., Wang, J., Sicherer, S., Groetch, M., Shreffler, W., Pyle, D., Kim, E., Keet, C., Kulis, M., Mudd, K., Sindher, S., Long, A., Scurlock, A. M., Jones, S. M., Leung, D., Lanser, B., Vickery, B., Ezhuthachan, I. D., …, & Wood, R. A. (2025). Introduction of allergenic foods after treatment with omalizumab. Journal of Allergy and Clinical Immunology, 156(2), 394-405. https://doi.org/10.1016/j.jaci.2025.05.014
Vancouver
Dantzer J, Virkud Y, Wang J, Sicherer S, Groetch M, Shreffler W, et al. Introduction of allergenic foods after treatment with omalizumab. Journal of Allergy and Clinical Immunology. 2025;156(2):394-405. doi:10.1016/j.jaci.2025.05.014
BibTeX
@article{Dantzer2025,
author = {Dantzer, Jennifer and Virkud, Yamini and Wang, Julie and Sicherer, Scott and Groetch, Marion and Shreffler, Wayne and Pyle, David and Kim, Edwin and Keet, Corinne and Kulis, Michael and Mudd, Kim and Sindher, Sayantani and Long, Andrew and Scurlock, Amy M and Jones, Stacie M and Leung, Donald and Lanser, Bruce and Vickery, Brian and Ezhuthachan, Idil D and Bird, J Andrew and Parrish, Christopher and Spergel, Jonathan M and Brown-Whitehorn, Terri and Ligueros-Saylan, Monica and Tassinari, Paolo and Iqbal, Ahmar and Sibanda, Dawn and Huckabee, Charmaine and Yovetich, Nancy and Rogers, Nicole and Lin, Adora and Wheatley, Lisa M and Togias, Alkis and Chinthrajah, R Sharon and Wood, Robert A},
title = {Introduction of allergenic foods after treatment with omalizumab},
journal = {Journal of Allergy and Clinical Immunology},
year = {2025},
volume = {156},
number = {2},
pages = {394--405},
doi = {10.1016/j.jaci.2025.05.014}
}
EUVIMED